It is important to note that there is a well-documented link between defects in MMR genes and CRC resistance to adjuvant 5-FU-based chemotherapy; however, the causal link of defective MMR with drug resistance or poor prognosis remains unclear [21–23, 31, 32]. This evidence concerns the gene MRC1 and colorectal carcinoma.